Korean J Med.  2006 Jun;70(6):688-694.

Carboplatin, ifosfamide, and etoposide chemotherapy for extensive-disease small cell lung cancer

• Ryu HJ
• Kim YN
• Gyeong SY
• Park SH
• An CH
• Bang SM
• Lee SP
• Lee JI
• Park JU
• Cho EK
• Jeong SH
• Shin DB
• Lee JH

Abstract

BACKGROUND: This prospective phase II study assessed the efficacy and toxicity of the combination of carboplatin, ifosfamide and etoposide for previously untreated patients with extensive-disease small cell lung cancer (ED-SCLC).
METHODS
Patients with ED-SCLC received a combination chemotherapy with carboplatin AUC 6.0 on day 1, ifosfamide 1200 mg/m2 on day 1-3, and etoposide 100 mg/m2 on day 1-3.
RESULTS
Forty-one patients received a median of six cycles of chemotherapy. A complete response was seen in 5 patients and a partial response was seen in 33 patients (overall response 95%). The median duration of the response was 5.1 months (95% CI; 3.4-6.8 months). The median time to progression and overall survival were 7.4 months (95% CI; 6.1-8.6 months) and 10.7 months (95% CI; 6.9-14.6 months), respectively, providing the one-year survival rate of 43.9%. Grade 3~4 anemia, neutropenia and thrombocytopenia occurred in 14%, 7% and 6% in a total of 212 cycles, respectively. Non-hematologic toxicities were generally mild and manageable. No treatment related death was observed.
CONCLUSIONS
The combination chemotherapy of carboplatin, etoposide and ifosfamide showed an effective response rate and acceptable toxicity.

Keyword

Ifosfamide; Etoposide; Carboplatin; Small cell lung carcinoma

MeSH Terms

Anemia
Area Under Curve
Carboplatin*
Drug Therapy*
Drug Therapy, Combination
Etoposide*
Humans
Ifosfamide*
Neutropenia
Prospective Studies
Small Cell Lung Carcinoma*
Survival Rate
Thrombocytopenia
Carboplatin
Etoposide
Ifosfamide